Zio­pharm craters on re­port of pa­tient death in gene ther­a­py study

Shares of Zio­pharm $ZIOP plunged this morn­ing af­ter Adam Feuer­stein at TheStreet broke the sto­ry that one pa­tient in its gene ther­a­py study dubbed Ad-RTS-hIL-12 died due to an in­tracra­nial he­m­or­rhage 15 days af­ter start­ing treat­ment. The note on the death — one of sev­er­al — was in­clud­ed in a slide pre­sen­ta­tion filed with the SEC. No­tably, Feuer­stein had the re­port even be­fore FDA reg­u­la­tors were no­ti­fied.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.